It’s Formulary Season, and Early Analyses Suggest Big Changes in How PBMs Approach Biosims
Shares:
There are two ways to think about this report from I-MAK that calculated that just four medicines -- Humira, Rituxan, Avastin and Lantus -- made more than $150 billion in
Confession: after a week of what feels like daily bombshells, I fear my brain is full. There’s plenty to talk about today that has gone under-recognized or under-analyzed, but there’s
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv